Primary Outcomes
| Bisphosphonate use | Denosumab use | |||||||||||
| Intervention baseline CAC (modified AU) | ∆ CAC from baseline (modified AU) | Control baseline CAC (modified AU) | ∆ CAC from baseline (modified AU) | P value | Effect size | Intervention baseline CAC (modified AU) | ∆ CAC from baseline (modified AU) | Control baseline CAC (modified AU) | ∆ CAC from baseline (Modified AU) | P value | Effect size | |
| Ariyoshi et al, 20067† | 4100±2440 | +880/12 months | 8990±15 180 | +2220/12 months | – | Not reported | ||||||
| Chen et al, 202016 | 2271±511 | −133±124/6 months | 2034±653 | +188±72/6 months | 0.03 | Not reported | ||||||
| Hill et al, 200214 | 108±290 (0–1650) | +2.4/month | 102±264 (0–1467) | +3.1 /month | 0.46 | Not reported | ||||||
| Nitta et al, 20048† | 1489 (168–8768) | −372/12 months | 1303 (231–3133) | +159/12 months | 0.01 | Not reported | ||||||
| Pawade et al, 202122* | 1268 (672–2065) | +326 (138–813)/24 months | 1127 (617–2059) | +354 (76–675)/24 months | 0.49 | Difference in means: 196 AU (95% CI −286 to 679 AU), p=0.42 Effect size powered at 40% | 1163 (598–2151) | +343 (198–804)/24 months | 1127 (617 to 2059) | +354 (76–675)/24 months | 0.41 | Difference in means: 169 AU (95% CI −304 to 643 AU), p=0.48 Effect size powered at 40% |
Data are either given as means±SD, with ranges in parentheses, or as means with ranges in parentheses.
*The study conducted by Pawade et al 22 reported specifically on the aortic valve calcium score (modified AU).
†The studies conducted by Ariyoshi et al 7 and Nitta et al 8 reported CAC in mm3 rather than modified AU.
AU, Agatston unit; CAC, coronary artery calcification.